This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: H. Lundbeck A/s. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Gennady N Smagin: Innovator in Depression Treatment
Introduction
Gennady N Smagin is a notable inventor based in Newark, DE (US). He has made significant contributions to the field of medicine, particularly in the treatment of depressive disorders. His innovative approach combines pharmacological agents to enhance therapeutic outcomes for patients suffering from melancholic features of depression.
Latest Patents
Gennady N Smagin holds a patent for the invention titled "Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features." This invention relates to the use of an opioid antagonist with kappa-activity in conjunction with vortioxetine, aimed at treating depressive disorders characterized by melancholic features. The patent also encompasses pharmaceutical compositions that include these agents, highlighting the potential for improved treatment options in mental health.
Career Highlights
Gennady is associated with H. Lundbeck A/S, a company renowned for its focus on psychiatric and neurological disorders. His work at Lundbeck has allowed him to contribute to groundbreaking research and development in the field of mental health, particularly in the pharmacological treatment of depression.
Collaborations
Gennady has collaborated with Connie Sanchez Morillo, further enhancing the innovative efforts within his field. Their partnership exemplifies the importance of teamwork in advancing medical research and developing effective treatment strategies.
Conclusion
Gennady N Smagin's contributions to the treatment of depressive disorders through his innovative patent demonstrate his commitment to improving mental health care. His work continues to pave the way for new therapeutic approaches that can significantly benefit patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile